We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Ark Ther Grp | AKT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 63.25 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 63.25 |
| Top Posts |
|---|
Posted at 25/11/2014 18:13 by hedgehog 100 mypension 21 Nov'14 - 19:14 - 3035 of 3038 0 0"To me this seems very disappointment. After months the best the directors can come up with is 15% of a loss making business with debt of over two million at 12% interest. In addition 10,000 shares will become 1000. Maybe I have read the runs wrongly" Mypension, 15% of the enlarged equity is a decent share: I wouldn't think that the average share of the enlarged equity for a shell post RTO (reverse takeover)is more than 20%. And it can be far less than 15%. The consolidation won't actually affect the value of your shares: you'll simply have far fewer with each one worth proportionally as much more (other things being equal). Joeblogg2, Both bosses are putting in relatively large sums. But at a price that appears to be at a steep discount. 21/11/2014 17:48 UKREG Ark Therapeutics Group PLC Posting of Circular " ...3. Subscription for New Ordinary Shares Conditional upon Admission, BFSL and a small number of other investors have agreed to subscribe in aggregate for GBP1.2 million of Subscription Shares at a subscription price of 10.1 pence per Subscription Share. BFSL has requested that in order to agree to the Revised BFSL Loan Arrangements, Iain Ross, Chairman of Ark and the CEO of PVG participate in the Subscription as to GBP70,456.49 and GBP267,734.54 respectively. The monies received from the Subscription will be primarily used as working capital in the Enlarged Group's business and, as a result of this investment, Ark Shareholders will own 15 per cent. of the Ordinary Shares at Admission. Following the Subscription of 11,859,007 Subscription Shares (following the Consolidation and Subdivision), the Enlarged Group will have 13,951,773 Ordinary Shares in issue. ... " There's not much detail on PVG yet, but it's fast-growing, has substantial revenue of £7.5M. p.a., and is the second biggest buying group in its sector: "Mr Tonner, aged 57, joined PVG's board as CEO in July 2007. Since that time revenues have increased from GBP2 million to GBP7.5 million per annum, PVG has completed six acquisitions and integrated the activities successfully, launched a new business, Premier Veterinary Alliance, to become the second biggest buying group in the sector and is now transacting business in Republic of Ireland and the Nordic region as well as the UK." Ten Bag Man may be on holiday. |
Posted at 14/11/2014 18:20 by ten bag man The Date of the Interim management statement has today been removed from the company investor page.(The old date shown was Wed 19th Nov 2014.) That date,(19th)was the last date that it could have been posted by the company under LSE rules. Now we have to ask why it has been removed.? I do not know,but here are some ideas. The 19th had a * showing the date could be moved but as I have pointed out in previous posts it could NOT be after the 19th Nov. So what has changed.? Well, if the deal is off and the company has hit the skids (bust),then all we will get is an RNS telling us that,(in which case no need to update the market with an IMS.) OR We get news of the RTO on Monday but the company does not want to let the news out till then. Or Any other ideas.? |
Posted at 06/11/2014 12:31 by ten bag man ARK'S investor page has just been updated:Interim management statement now due on the 19th. |
Posted at 06/11/2014 07:15 by ten bag man We should get some kind of update this time tomorrow.(As per ARK'S investors page) |
Posted at 02/11/2014 23:25 by runwaypaul may be of interestFINRA, SEC Warn Investors About Penny Stock Scams Hyping Dormant Shell Companies WASHINGTON—The Financial Industry Regulatory Authority (FINRA) and the Securities and Exchange Commission's (SEC) Office of Investor Education and Advocacy today issued an alert warning investors that some penny stocks being aggressively promoted as great investment opportunities may in fact be stocks of dormant shell companies with little to no business operations. The investor alert provides tips to avoid pump-and-dump schemes in which fraudsters deliberately buy shares of very low-priced, thinly traded stocks and then spread false or misleading information to pump up the price. The fraudsters then dump their shares, causing the prices to drop and leaving investors with worthless or nearly worthless shares of stock. Gerri Walsh, FINRA's Senior Vice President for Investor Education, said, "Investors should be on the lookout for press releases, tweets or posts aggressively promoting companies poised for explosive growth because of their 'hot' new product. In reality, the company may be a shell, and the people behind the touts may be pump-and-dump scammers looking to lighten your wallet." "Fraudsters continue to try to use dormant shell company scams to manipulate stock prices to the detriment of everyday investors," said Lori J. Schock, Director of the SEC's Office of Investor Education and Advocacy. "Before investing in any company, investors should always remember to check out the company thoroughly." The investor alert highlights five tips to help investors avoid scams involving dormant shell companies: Research whether the company has been dormant—and brought back to life. You can search the company name or trading symbol in the SEC's EDGAR database to see when the company may have last filed periodic reports. Know where the stock trades. Most stock pump-and-dump schemes involve stocks that do not trade on The NASDAQ Stock Market, the New York Stock Exchange or other registered national securities exchanges. Be wary of frequent changes to a company's name or business focus. Name changes and the potential for manipulation often go hand in hand. Check for mammoth reverse splits. A dormant shell company might carry out a 1-for-20,000 or even 1-for-50,000 reverse split. Know that "Q" is for caution. A stock symbol with a fifth letter "Q" at the end denotes that the company has filed for bankruptcy. FINRA is the largest non-governmental regulator for all securities firms doing business in the United States. FINRA is dedicated to investor protection and market integrity through effective and efficient regulation and complementary compliance and technology-based services. FINRA touches virtually every aspect of the securities business—from registering and educating all industry participants to examining securities firms, writing and enforcing rules and the federal securities laws, informing and educating the investing public, providing trade reporting and other industry utilities, and administering the largest dispute resolution forum for investors and registered firms. For more information, please visit our website at www.finra.org. |
Posted at 02/11/2014 08:34 by ten bag man Looks like we will get an update on the RTO this Friday. (7th)It is down for one day later than last year, but the * at the bottom says its subject to change. All fully listed companies have to put our interim management statements twice a year. Must be a good chance the RTO paper work will be sent to share holders the same day. "ARK Investors company web page" Event Date 2013 Annual Report Posted 30 April 2014 2014 Annual General Meeting 30 June 2014 1st Interim Management Statement Announced 13 May 2014 Half Year End 30 June 2014 2014 Half Yearly Results Announced 1 August 2014 2nd Interim Management Statement Announced 7 November 2014* Financial Year End 31 December 2014 * Date may be subject to change |
Posted at 30/4/2014 22:16 by hedgehog 100 30/04/2014 07:01 UKREG Ark Therapeutics Group PLC Final Results"London, UK, 30 April 2014- Ark Therapeutics Group plc (LSE: AKT) today announces its audited results for the year ended 31 December 2013. Financial highlights -- Total revenues and other income for the year ended 31 December 2013 of GBP0.3m (31 December 2012: GBP1.9m) -- Net assets at 31 December 2013 of GBP0.9m (31 December 2012: net liabilities of GBP0.2m) -- Cash and short-term deposits of GBP0.8m (31 December 2012: GBP1.7m) -- Profit for the year after tax was GBP1.1m (31 December 2012: loss after tax was GBP2.5m) -- On 15 March 2013 the Company disposed of its operating subsidiaries - - Post-period the Company signed heads of terms in connection with the possible acquisition of a revenue-generating and profitable UK-based private company in the healthcare support services sector A full copy of the Company's Annual Report and Accounts for the year ended 31 December 2013 is available on its website at www.arktherapeutics. Disclosure & Transparency Rule ("DTR") 6.3.5 requires the Company to disclose to the media certain information from its Annual Report, if that information is of a type that would be required to be disseminated in a half-yearly report. Accordingly, this announcement should be read in conjunction with and is not a substitute for reading, the full Annual Report and Accounts. Together these constitute the information required by DTR 6.3.5, which is required to be communicated in unedited full text through a Regulatory Information Service. The information included in this announcement is extracted from the 2013 Annual Report which was approved by the Directors on 29 April 2014. Defined terms used in the announcement refer to terms as defined in the 2013 Annual Report unless the context otherwise requires. Annual General Meeting The Notice convening the next Annual General Meeting, which is expected to take place by the end of June 2014 at the offices of Ashurst, Broadwalk House, 5 Appold Street, London EC2A 4HA will be posted separately to shareholders nearer the time. For further information please contact: Ark Therapeutics Group plc Tel: +44 (0)207 002 1005 Iain G Ross, Non-Executive Chairman David Venables, Non-Executive Director " |
Posted at 24/3/2014 07:42 by tara7 FOUND THIS ON THE WEB:Well worth a read. AKT is fully listed [not on AIM] Cash Shells and Standard Listings 29/10/2012 Cash shells or SPACs (special purpose acquisition companies) are purpose-built vehicles with a stock market quote and a board of directors, but no active business and no assets other than a strong management (or advisory) team with specific sector expertise and the funds raised from financial backers (which will typically include management). The structure gives managers a ready-made stock market listing, a cash war chest and an acquisition currency at a time when, owing to global financial circumstances, the cost of financing is high and transactions are difficult to execute. The trend Cash shells were extremely popular on the AIM market seven years ago, arriving in such numbers that the LSE was forced to tighten the rules to safeguard the market's reputation. In March 2005 alone, 31 cash shells rushed to list to beat the introduction of the rule changes the following month, which stipulated that a cash shell must raise a minimum of £3 million, a figure deemed high enough to require at least some institutional interest. Other rule changes included tightening up the stated investing policy and a requirement to seek shareholders' consent annually to the continuance of the policy should it not be substantially implemented within 18 months of listing. The last couple of years have seen a number of cash shells not only returning to AIM, but, for the first time, obtaining admission to the Official List of the United Kingdom Listing Authority (UKLA) by way of a Standard listing. The timing of the appearance of these cash shells is a function of the regulatory environment of these markets and the volatile nature of the present economic climate. The cash shell structure is designed to take advantage of any dislocation in the market to acquire assets at favourable prices. When asset valuations start to rise, the opportunity for these acquisition vehicles could well disappear. The regulatory environment for Standard listed cash shells Access to the Premium listing segment of the Official List, whereby the issuer is subject to onerous eligibility and continuing obligation requirements and is potentially eligible for inclusion in the FTSE indices, is not possible for a cash shell; there are a number of entry requirements that a shell company simply would not be able to satisfy, which do not apply to Standard listing or to AIM applicants. In particular, a Premium listing applicant is required to have unqualified, consolidated, independently audited accounts covering a three-year period; a revenue earnings record in respect of at least 75 per cent of its business for a three year period; and a history of control over the majority of its assets for at least a three-year period. AIM cash shells are more heavily regulated than those with a Standard listing. In the last two years, management teams and their financial backers have increasingly been making a virtue of the minimal regulatory requirements applicable to cash shells with a Standard listing while raising very significant amounts of money on IPO. The key factor, as had been made explicit in the listing documents, was that a Standard listed issuer was not required to obtain shareholder approval for the acquisition of a target. While a Standard listing applicant must prepare a prospectus that is approved by the UKLA, it otherwise benefits from the relaxation of a number of rules that are applicable to Premium listed and/or AIM companies. Currently under the UKLA's Listing Rules, a Standard listed cash shell is not: required to appoint a financial adviser or sponsor on IPO or on a continuing basis (an AIM company is required to appoint a "nominated adviser" (or "nomad") at all times); subject to the "Listing Principles" set out in the UKLA Listing Rules; subject to any minimum fund raising requirement (other than to have a market capitalisation of £700,000 as set out in the UKLA Listing Rules applicable to all Official List companies); required to set out a formal investing policy or to implement it within any particular time frame (it follows that a change in investing policy is not subject to shareholder approval, nor is its ongoing validation in the event of failure to implement it within a stated period); required to seek shareholder approval for significant transactions (including transactions which would be categorised as a reverse takeover or a fundamental disposal of business); subject to the restrictions on share dealing (by the issuer or management); subject to restrictions as to the price and nature of share issuances or buy backs (although a Standard listed issuer must publish a prospectus if it issues, over a 12-month period, further securities that represent 10% or more of the securities of a class already admitted to trading); required to adhere to certain specific ongoing disclosure requirements (other than the general obligation to disclose price-sensitive information); required to seek shareholder or sponsor approval for related party transactions (a nomad must confirm to an AIM listed issuer that such a transaction is fair and reasonable insofar as the shareholders are concerned and certain prescribed details of the transaction must be notified to the market); required to offer new shares for cash on a pre-emptive basis to shareholders (indeed, typically any statutory pre-emption rights are disapplied prior to the IPO in connection with any shares to be issued to finance an acquisition); and required to comply with any corporate governance codes (although certain disclosures as to internal control and risk management procedures must be made in the issuer's annual report). In practice, issuers tend to voluntarily commit to certain standards or restrictions in relation to some of the above points, although the UKLA has no power to police compliance with such commitments. Notable transactions involving Standard listed cash shells Horizon Acquisition Company plc raised £417.7 million on its IPO and Standard listing in February 2010. Horizon achieved its investment goal by acquiring APR Energy, a Florida-based temporary power provider, in June 2011 for £527 million (£221 million in cash and £306 million in Horizon shares). The group retains its Standard listing. In June 2010 came the IPO and Standard listing of Nat Rothschild's Vallar plc, raising £687 million to fund acquisitions in the metals and mining industry. June 2011 saw the acquisition by Vallar of PT Bumi Resources Minerals Tbk, an international mining company, and a reorganisation resulting in the introduction of Bumi plc as the new Premium listed parent company. The acquisition price represented a total consideration of £1.27 billion. Marwyn Management Partners plc obtained a Standard listing in January 2011, raising a relatively modest £6 million. In August 2011, Marwyn acquired AIM-listed Praesepe plc, a gaming company, having raised approximately £40 million to complete the acquisition. Marwyn's investment objective is to acquire controlling and non-controlling interests in public and private companies, appointing operational managers with a "buy and build" strategy. The IPO in February 2011 of Justice Holdings Limited launched by, among others, Nicolas Berggruen, the billionaire backer of hedge fund GLG and Pearl Insurance, raised £900 million. Justice Holdings announced in April 2012 an investment of US$1.4 billion for 29% of Burger King. As part of the transaction, Justice merged with the new Burger King holding company, de-listed from the London Stock Exchange and re-listed on the New York Stock Exchange. Vallares plc, the second of Nat Rothchild's vehicles, raised £1.35 billion in June 2011 with a focus on oil and gas assets. In September 2011, Vallares announced the acquisition of Genel Energy International for US$2.1 billion. The enlarged group retains its Standard listing. Practical considerations and recent developments These listings, together with the record of successfully completed acquisitions, represent some of the most significant recent transactions in the London market and clearly show that the cash shell concept, particularly by way of Standard listing, remains compelling in current market conditions. A management team or group of investors thinking of establishing a London-listed cash shell for investment purposes and debating whether to opt for an AIM or Standard listing, should consider the following, in addition to the points referred to above: whilst there are a number of advantages of the Standard listing regime over AIM, the involvement of the UKLA in establishing eligibility for listings and approving the prospectus could lead to a longer IPO timetable compared to an AIM listing, where such matters are dealt with by the nomad; having considered the feedback from its consultation paper (CP12/2) issued in January 2012, in October 2012 the UKLA adopted the proposals to update the reverse takeover regime as applicable to Premium and Standard listed issuers. Under the Technical Note issued by the UKLA previously in force, transactions by Standard listed shells were treated as reverse takeovers in certain respects, namely (i) on completion of an acquisition, the company's shares would have been cancelled and the enlarged group would have had to re-apply for a listing on the back of a new prospectus; and (ii) listing may have been suspended pending publication of a new prospectus if there was insufficient information in the market on the target at the time of the announcement. The rule changes do not require that a Standard listed company seek shareholder approval for a reverse takeover. The revised Listing Rules have sought to reduce the information requirements that need to be met, after announcement of a transaction, in order for a suspension to be avoided, for Premium and Standard listed companies alike, and provide that if the company is acquiring another Premium or Standard listed entity and can establish eligibility for a continued listing in respect of the enlarged group, cancellation and re-admission (which would need a UKLA-approved prospectus to be prepared and published) can be avoided; whilst the minimum market capitalisation on listing of a Standard listed shell could, under the Listing Rules, be £700,000 the UKLA may query whether an issuer can properly carry out its investment policy with such a small amount of working capital. However, if a small shell listing is envisaged, this figure could still be significantly lower than the £3 million required on AIM; the founder incentive structures for the large Standard listings mentioned above have typically been complex, involving a mixture of straight equity and convertible securities, giving the founders an incentive based both on making an acquisition and the longer-term performance of the enlarged group. Further, management of the company and deal selection and execution are often outsourced, under an advisory agreement, to an unregistered advisory entity owned and operated by the founders. The founders have tended to invest a significant proportion of the IPO funding from their own resources. Note that the revised listing rules adopted in October 2012 as a result of the consultation exercise following CP12/2, make the principals of the advisory firm to a Standard listed cash shell (a so-called "externally managed company") responsible for any prospectus issued by the company and subject to rules on disclosure of share dealings. AIM cash shell listings, perhaps reflecting their smaller size, have tended to utilise simpler share, board and incentive arrangements. There is no reason why the AIM style is not equally appropriate for a Standard cash shell listing; as the above example transactions show, there are a variety of potential alternatives in respect of the continued listing of the enlarged group following completion of an acquisition. As stated above, the listing on the Standard segment would (unless the target is a Premium or Standard listed company) be cancelled on completion of a reverse takeover, and it would be possible to list the enlarged group on AIM instead. Otherwise, cancellation of a company's Standard listing at the company's request does not require shareholder approval; the requirement for a Standard listed company to prepare a prospectus if it wishes to issue 10% or more of its shares is not, in practice, likely to create extra work, expense or delay as the cash shell is likely to only issue new shares in connection with an acquisition, which would in any event require the production of a prospectus, or AIM admission document, for the enlarged group; it should be noted that the flexibility to make major disposals without seeking shareholder approval is a significant feature of the Standard listing regime, and may be of benefit to the company as its business grows over time. Recently, HMV Group sought shareholder approval to move from a Premium listing to a Standard listing (rather than AIM) explicitly to benefit from this flexibility in the context of the company's strategic review process. The listing category transfer was approved by 99.32% of the votes cast at the EGM; and it should be noted that the requirements for the inclusion and content of a competent person's report (CPR) in the prospectus for a Standard listing may be more flexible than those applicable to an AIM admission document. In relation to a Standard listing, the rules governing prospectuses specify content requirements that are recommended rather than compulsory (in particular, there is no compulsory requirement for a valuation of reserves and resources), provide that a site visit is not compulsory (being a matter of professional judgment for the competent person acting in accordance with the approved mineral codes), and establish that it may be possible to avoid the preparation of a CPR altogether by passporting a previously prepared CPR and/or annual market updates of reserves and resources on an overseas market or trading facility. |
Posted at 23/3/2014 20:57 by tara7 MORE FROM TODAYS SUNDAY TIMES." There is a palpable sense that British investors are re-discovering a taste for biotech stocks, which have not been in favour for years. Last week's float of Circassia, which is developing treatments to prevent allergic reaction to cats and pollen, is a sure sign these stocks are coming back into vogue" |
Posted at 23/3/2014 14:30 by tara7 ARK: [code AKT]Best case scenario; RTO by a massive Biotech company that is in profit. ARK"S tax loss would be worth many times ARK"S share price. Market cap £1M today V £24M of value [20% of £120M]. Second best scenario: ARK is taken out for its tax loss by any company,[has to be a biotech]again worth many times todays share price. Third best scenario: A large unlisted company from any sector does an RTO into ARK [Tax loss could not be used] This would be worth the cash within ARK plus in my view 100% to 1,000% depending on the terms, new investors, and so on.[We have seen companies do 500% plus within hours in the last month or two after deals have been done. The fourth best scenario: no deal is done, and the company shuts shop and hands back all the cash;[as they have said they will do.] Cash should be £1.5M as of 31/12/13 less running costs of £150,000 for the six months up to 31/12/13.[could be a tad less if the company has not pulled in all the monies due, by that date] MARKET CAP TODAY £1.1M |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
